ERBB2 and breast carcinoma: Although no clinical evidence is currently available in terms of their actionability in PTs or sarcomas, clinical data support the potential targeting of these AKT, ERBB2, and PIK3CA hotspot mutations in breast cancer (OncoKB level of evidence 3A;23 Fig. 2 and Supplementary Table 3).